Results of pathogenetic therapy with the drug N-Pentoxynial in children with current latent CMV/EBV infection

LLP Medactiv, Almaty, Republic of Kazakhstan, Raushan Idrissova, Farida Mustafaeva, Madina Zhaksybek, Zhannat Idrissova

2020

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.31082/1728-452x-2020-213-214-3-4-33-39
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In the perinatal and early postnatal period, congenital (antenatal) and intrauterine (intra- and perinatal) CMV are more often manifested by lesions of the liver, brain and organ of vision. Objective. To study the effect of pathogenetic therapy with the metabolic and hepatoprotective drug N-Pentoxinial on the course of persistent CMV/EBV infection of perinatal genesis in children. Material and Methods. The course of latent perinatal cytomegalovirus (CMV) and Epstein-Bar viral infections in children was studied against the background of antiviral treatment (specific against CMV/ EBV immunoglobulin - Neocytect and recombinant alpha-interferon - Viferon No. 10), followed (immediately after 5-7 days after antiviral) by the appointment of 1-2 courses of N-Pentoxinal for 10-20 days. The main group consisted of 20 children (average age 5.4±1.4 years), the control group consisted of 10 children (average age 5.1±1.7 years). All underwent general clinical and virological studies to confirm the diagnosis. Result and discussions. The results obtained indicate that the addition of N-pentoxynial to the basic antiviral therapy for CMV and EBV infection in children improves (accelerates) the elimination of the virus from biological fluids (blood and urine), as well as more rapid normalization of transaminases and alkaline phosphatase. There were no reliably proven allergic reactions. Conclusions. The drug N-Pentoxinial can be prescribed after antiviral therapy for perinatal CMV, EBV infection in order to consolidate the results of antiviral treatment and normalize liver function, especially bile secretion. Keywords: latent perinatal cytomegalovirus/Epstein-Barr viral infection, children, therapy.